KEVIN LEE: Open Payments
NPI 1952852196 · BROOMFIELD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,227 in 107 payments from 17 companies in 2025. Trend: 2023 $215 · 2024 $2,771 · 2025 $2,227
Food & beverage: $2,227
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $621 |
| Janssen Biotech, Inc. | 13 | $454 |
| Gilead Sciences, Inc. | 13 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $180 |
| Regeneron Healthcare Solutions, Inc. | 5 | $131 |
| Madrigal Pharmaceuticals | 5 | $102 |
| GENZYME CORPORATION | 4 | $84 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| QOL Medical, LLC | 3 | $63 |
| PFIZER INC. | 3 | $61 |
Products named: TREMFYA, RINVOQ, DUPIXENT, LINZESS, ENTYVIO, REZDIFFRA, VOQUEZNA, Sucraid.
Industry payments across CO — which companies pay providers there.
